Medicus Pharma (MDCX) to Release Quarterly Earnings on Monday

Posted by on May 4th, 2026

Medicus Pharma (NASDAQ:MDCX – Get Free Report) is projected to announce its results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Medicus Pharma (NASDAQ:MDCX – Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.50). On average, analysts expect Medicus Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock traded up $0.00 during trading on Monday, hitting $0.29. 401,029 shares of the company were exchanged, compared to its average volume of 4,601,696. The firm has a market capitalization of $12.04 million, a P/E ratio of -0.10 and a beta of -0.47. Medicus Pharma has a 1-year low of $0.27 and a 1-year high of $8.94. The firm’s fifty day moving average price is $0.59 and its 200 day moving average price is $1.35.

Hedge Funds Weigh In On Medicus Pharma

A number of large investors have recently bought and sold shares of the company. Armistice Capital LLC acquired a new position in Medicus Pharma during the 4th quarter worth approximately $2,771,000. Private Advisor Group LLC boosted its position in Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after acquiring an additional 5,500 shares during the last quarter. Jane Street Group LLC acquired a new position in Medicus Pharma during the 4th quarter worth approximately $92,000. Wilmington Savings Fund Society FSB boosted its position in Medicus Pharma by 100.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after acquiring an additional 25,622 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MDCX shares. Roth Mkm started coverage on Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating for the company. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Medicus Pharma currently has a consensus rating of “Hold” and an average price target of $14.50.

Check Out Our Latest Report on MDCX

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.

Featured Stories

Earnings History for Medicus Pharma (NASDAQ:MDCX)

Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.